Dr. Maki brings nearly 20 years of biotechnology and pharma business development expertise as Company rapidly advances its powerful LNP platform to deliver mRNA-based therapies MENLO PARK, Calif. & ...

TOKYO--(BUSINESS WIRE)--Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc.

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

At Bayer, a groupwide restructuring is being rolled out as a top priority. But, to Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, ...

In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...

Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as ...

During a June 2025 trade mission to the United Kingdom and France, Virginia Economic Development Partnership leaders and then-Gov. Glenn Youngkin met with AstraZeneca officials. Thirty-three days ...

Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch "The third quarter represented a transformational period for ...

Dynamic Vapor Sorption (DVS) is a potent analytical technique used in the pharmaceutical industry to determine how much vapor a sample absorbs or desorbed under regulated temperature and humidity ...